Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer

Human Pathology

Volumn 29, Issue 9, 1998, Pages 949-954

  Bubendorf, Lukas ^a   Tapia, Coya ^a   Gasser, Thomas C ^a   Casella, Roberto ^a   Grunder, Bettina ^a   Moch, Holger ^a   Mihatsch, Michael J ^a   Sauter, Guido ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Bcl 2; Ki67; p53; Prognosis; Prostate cancer

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

EID: 0031689226     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90199-X     Document Type: Article

References (40)

1. Boyle P, Maisonneuve P, Napalkov P: Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 46:47-55, 1995
2. Von Eschenbach AC: The biologic dilemma of early carcinoma of the prostate. Cancer 78:326-329, 1996
3. Grignon DJ, Hammond EH: College of American pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors: Report of the prostate cancer working group. Arch Pathol Lab Med 119:1122-1126, 1995
4. Bubendorf L, Sauter G, Moch H, et al: Ki67 labeling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178:437-441, 1996
5. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al: Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 156:1064-1068, 1996
6. Stattin P, Damber JE, Karlberg L, et al: Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 157:219-222, 1997
7. Bubendorf L, Sauter G, Moch H, et al: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148:1557-1565, 1996
8. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992
9. Visakorpi T, Kallioniemi OP, Heikkinen A, et al: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992
10. Grignon DJ, Caplan R, Sarkar FH, et al: p53 status and prognosis of locally advanced prostatic carcinoma: A study based on RTOG 8610. J Natl Cancer Inst 89:158-165, 1997
11. Isaacs JT: Molecular markers for prostate cancer metastasis: Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol 150:1511-1521, 1997
12. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology: The Prostate. Philadelphia, PA, Lea and Febiger, 1977, pp 171-197
13. Hitchcock CL: Ki-67 staining as a means to simplify analysis of tumor cell proliferation. Am J Clin Pathol 96:444-446, 1991
14. Linden MD, Torres FX, Kubus J, et al: Clinical application of morphologic and immunocytochemical assessments of cell proliferation. AJCP 5:S4-S13, 1992 (suppl 1)
15. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994
16. Cupp MR, Bostwick DG, Myers RP, et al: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153:1543-1548, 1995
17. Bostwick DG: Grading prostate cancer. Am J Clin Pathol 102:S38-S56, 1994
18. Spires SE, Cibull ML, Wood DJ, et al: Gleason histologic grading in prostatic carcinoma: Correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 118:705-708, 1994
19. Wilt TJ, Brawer MK: The prostate cancer intervention versus observation trial (PIVOT). Cancer 75:1963-1967, 1995
20. Von Eschenbach AC, Brawer MK, Di Sant'Agnese PA, et al: International consultation on prostatic intraepithelial neoplasia and pathologic staging of prostatic carcinoma: Exploration of new pathologic factors in terms of potential for prognostic significance and future application. Cancer 78:372-375, 1996
21. Noordzij MA, van der Kwast TH, van Werden WM, et al: Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-I in formalin-fixed, paraffin-embedded prostatic cancer tissues. Prostate 27:154-159, 1995
22. Oomens EH, van Steenbrugge G, van der Kwast TH, et al: Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the growth fraction of human prostatic carcinoma. J Urol 145:81-85, 1991
23. Cher ML, Chew K, Rosenau W, et al: Cellular proliferation in prostatic adenocarcinoma as assessed by bromdeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 26:87-93, 1995
24. Mashal RD, Lester S, Corless C, et al: Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 56:4159-4163, 1996
25. Harper ME, Goddard L, Wilson DW, et al: Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 21:75-84, 1992
26. Lu QL, Abel P, Foster CS, et al: bcl-2: Role in epithelial differentiation and oncogenesis. HUM PATHOL 27:102-110, 1996
27. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994
28. Krajewska M, Kraiewska S, Epstein JI, et al: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567-1576, 1996
29. Apakama I, Robinson M, Walter N, et al: Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 74:1258-1262, 1996
30. Matsushima H, Hosaka Y, Suzuki M, et al: bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Int J Urol 3:113-117, 1996
31. Furuya Y, Krajewski S, Epstein JI, et al: Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 2:389-398, 1996
32. Bauer JJ, Sesterhenn IA, Mostofi FK, et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156:1511-1516, 1996
33. Cohen RJ, Cooper K, Haffejee Z, et al: Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Pathology 27:229-232, 1995
34. Stattin P, Damber JE, Karlberg L, et al: Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 24:257-264, 1996
35. Noordzij MA, Bogdanowicz JFAT, van Krimpen C, et al: The prognostic value of pretreatment expression of androgen receptor and Bcl-2 in hormonally treated prostate cancer patients. J Urol 158:1880-1885, 1997
36. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 83:323-331, 1997
37. Hall PA, Lane DP: p53 in tumor pathology: Can we trust immunohistochemistry? Revisited! J Pathol 172:1-4, 1994
38. Stricker HJ, Kay JK, Linden MD, et al: Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 47:366-369, 1996
39. Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al: Alterations of the tumor suppressor gene p53 in high fraction of hormone refractory prostate cancer. J Urol 154:414-421, 1995
40. Shurbaji MS, Kalbfleisch KH, Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. HUM PATHOL 26:106-109, 1995